Compare DXR & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXR | INCR |
|---|---|---|
| Founded | 1970 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 47.4M |
| IPO Year | 1995 | 2021 |
| Metric | DXR | INCR |
|---|---|---|
| Price | $10.53 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 61.9K |
| Earning Date | 02-27-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | $69.54 |
| Revenue Next Year | $74.79 | $41.75 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $0.68 |
| 52 Week High | $14.76 | $1.77 |
| Indicator | DXR | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 45.90 |
| Support Level | $9.64 | $0.84 |
| Resistance Level | $10.65 | $0.98 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 64.78 | 4.63 |
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.